Month: September 2022

Notice of redemption of convertible bonds PKG4

Written by Customer Service on September 19, 2022. Posted in Public Companies.

Notice of redemption of convertible bonds PKG4 AS Pro Kapital Grupp informs that it is redeeming 27 999 “EEK 7.00 PRO KAPITAL GRUPP CONV. BOND PKG4 10-2020” convertible bonds (with ISIN EE3300109248) in total nominal value of 279 990 Estonian kroons and issue value of 78 397.20 euros and has submitted the Nasdaq Central Depository of Securities the application to delete the bonds from the register. The convertible bonds bore an annual interest of 7%. The issue price of each convertible bond was 2.80 euros. The list of bondholders was fixed on 16 September 2022 and redemption payment will be made on 30 September 2022. Edoardo Axel Preatoni Member of the Management Board +372 614 4920prokapital@prokapital.ee

Proactive news headlines including Astro Resources, Aeris Resources, Buru Energy and Animoca Brands Corporation

Written by Customer Service on September 19, 2022. Posted in Mergers And Acquisitions.

Sydney, Sept. 19, 2022 (GLOBE NEWSWIRE) — Proactive, provider of real-time news and video interviews on growth companies listed in Australia, has covered the following companies:Astro Resources NL (ASX:ARO) has revealed a significant increase in indicated resources to 78 million tonnes at 4.8% THM (total heavy minerals) at its Governor Broome Heavy Mineral Sands Project in Western Australia. Click here Aeris Resources Ltd (ASX:AIS) has further enhanced the copper potential of Murrawombie deposit within the Tritton operations in New South Wales with high-grade copper intersected below the resource. Click here Buru Energy Ltd (ASX:BRU) has responded to news that Origin Energy intends to exit upstream exploration permits and divest 50% of its joint venture interests with Buru in the Canning Basin. Click here Animoca Brands Corporation...

Zealand Pharma Presents Data from Phase 3 Trial of Dasiglucagon in Congenital Hyperinsulinism at the 60th Annual ESPE Meeting

Written by Customer Service on September 19, 2022. Posted in Public Companies.

Press release – No. 5 / 2022 Zealand Pharma Presents Data from Phase 3 Trial of Dasiglucagon in Congenital Hyperinsulinism at the 60th Annual ESPE MeetingDasiglucagon significantly reduced the requirement for intravenous glucose to maintain glycemia in newborns and infants with CHI (Part 1 of Phase 3 trial) Dasiglucagon reduced time in hypoglycemia and enabled discontinuation of intravenous glucose in most infants and limited the need for pancreatectomy (Part 2 of Phase 3 trial) Results support the potential for dasiglucagon to be a novel, effective, and well tolerated treatment for infants with CHI dependent on intravenous glucoseCopenhagen, DK and Boston MA, U.S. September 19, 2022 – Zealand Pharma A/S (CVR-no. 20045078,) a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today...

INVL Partner Global Infrastructure Fund I raised an additional USD 1.895 million

Written by Customer Service on September 19, 2022. Posted in Public Companies.

The INVL Partner Global Infrastructure Fund I, which invests in a fund of infrastructure assets managed by a company of global stature with a long track record, raised another USD 1.895 million from 7 investors. An offering of the fund’s investment units ended on 15 September, bringing the capital raised to date by the INVL Partner Global Infrastructure Fund I to USD 39.390 million. A total of 95 investors have invested in the fund which invests in infrastructure in member states of the Organisation for Economic Co-operation and Development (OECD). “Investor sentiment in the capital markets is still weighed down not just by the war in Ukraine but also by inflation, rising interest rates and slowing economic growth. But investors notice alternative ideas for investing in world-class funds, diversifying their portfolios and protecting...

GENFIT to Acquire Clinical-stage Biopharmaceutical Company Versantis, expanding its Portfolio in Liver Diseases

Written by Customer Service on September 19, 2022. Posted in Mergers And Acquisitions.

Further consolidates GENFIT’s position as a leader in acute-on-chronic liver failure (ACLF) Significantly expands GENFIT’s pipeline with VS-01-ACLF, a Phase 2 ready program based on first-in-class scavenging liposomes technology, VS-01-UCD, a pediatric program focused on urea cycle disorder (UCD), and VS-02-HE, an early-stage program focused on hepatic encephalopathy (HE) Combines Versantis’ expertise with GENFIT’s know-how in conducting complex development programs in liver diseases, to strengthen and accelerate research and development Deal terms include a payment of CHF40 million, an aggregate of CHF65 million of potential additional payments contingent on successful clinical and regulatory milestones, and one-third of the net proceeds from the potential sale of a Priority Review Voucher, if awarded by the FDA GENFIT will host a live...

Bureau Veritas: acquisition of Galbraith Laboratories Inc., a US expert in Healthcare analytical testing solutions

Written by Customer Service on September 19, 2022. Posted in Mergers And Acquisitions.

PRESS RELEASE Neuilly-sur-Seine, France – September 19, 2022 Bureau Veritas acquires Galbraith Laboratories Inc., a US expert in Healthcare analytical testing solutions Expanding BV’s position in Consumer Healthcare, Personal Care & Industrial Chemical markets Bureau Veritas, a world leader in testing, inspection and certification, announced the acquisition of Galbraith Laboratories Inc., an expert in advanced analytical solutions in North America. The acquisition will further position Bureau Veritas in the Consumer Healthcare and Industrial Chemical supply chain by connecting our existing services to support upstream research and product development through manufacturing to the end consumer. Galbraith Laboratories Inc. offers testing solutions to a wide range of industry segments, including chemicals, healthcare, cosmetics, consumer,...

European Commission approves Roche’s Vabysmo, the first bispecific antibody for the eye, for two leading causes of vision loss

Written by Customer Service on September 19, 2022. Posted in Public Companies.

Phase III data that showed people with nAMD and DME treated with Vabysmo up to every four months achieved similar outcomes compared to receiving treatment every two months with aflibercept In addition, patients treated with Vabysmo received up to 33% fewer median number of injections compared to aflibercept Reducing the number of eye injections over time could offer a less burdensome treatment schedule for individuals, their caregivers and healthcare systems Vabysmo simultaneously targets and inhibits two disease pathways involving Ang-2 and VEGF-A linked to a number of vision-threatening retinal conditionsBasel, 19 September 2022 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission (EC) approved Vabysmo® (faricimab) for the treatment of neovascular or ‘wet’ age-related macular degeneration (nAMD)...

Pixium Vision announces reaching its enrollment target in the European pivotal trial PRIMAvera and implantations planned to be completed by end 2022

Written by Customer Service on September 19, 2022. Posted in Public Companies.

Pixium Vision announces reaching its enrollment target in the European pivotal trial PRIMAvera and implantations planned to be completed by end 2022The target number of 38 patients have been enrolled at clinical sites in France, Germany, the UK, the Netherlands, and Italy Waiting list for additional patients initiated to replace potential pre-implantation drop-outs and ineligibility Implantations due to be completed by the end of 2022; PRIMAvera read-out expected around the end of 2023Paris, France, September 19, 2022 – 07:00 CET – Pixium Vision SA (Euronext Growth Paris – FR0011950641; Mnemo: ALPIX), a bioelectronics company that develops innovative bionic vision systems to enable patients who have lost their sight to live more independent lives, announces today the completion of patient enrollment in the PRIMAvera pivotal...

Sandoz announces further progress on its biosimilar pipeline, with release of positive results for denosumab integrated Phase I/III clinical trial

Written by Customer Service on September 19, 2022. Posted in Public Companies.

ROSALIA study met primary endpoints, confirming proposed biosimilar denosumab matches reference product in terms of pharmacokinetics, pharmacodynamics, efficacy, safety and immunogenicity in postmenopausal women with osteoporosisOsteoporosis accounts for 8.9 million bone fractures annually, including debilitating hip fractures – a number set to increase substantially over next two decades1Positive trial results follow filing acceptances for two other proposed Sandoz biosimilars, adalimumab HCF and natalizumab, by both EMA and FDABasel, September 19, 2022 – Sandoz, a global leader in off-patent (generic and biosimilar) medicines, today announces further progress on its biosimilar pipeline, with the release of positive results from the integrated ROSALIA Phase I/III clinical trial study for its proposed biosimilar denosumab. “Biosimilars...

BYND Cannasoft Enterprises Inc. Signs Agreement for the Acquisition of Israeli-Based Zigi Carmel Initiatives & Investments Ltd. In a Share Swap Agreement Valued at US $28 Million

Written by Customer Service on September 19, 2022. Posted in Mergers And Acquisitions.

ZC owns the patent pending intellectual property for a CBD-based therapeutic device combined with software designed to treat phenomena related to women’s health issues by regulating the flow of low-concentration CBD oils into the soft tissues of the female reproductive system VANCOUVER, British Columbia, Sept. 18, 2022 (GLOBE NEWSWIRE) — BYND Cannasoft Enterprises Inc. (NASDAQ: BCAN) (CSE: BYND) (“BYND” or the “Company”) announced today that it has signed a share purchase agreement to acquire 100% ownership of Zigi Carmel Initiatives & Investments Ltd. (“ZC”) which holds the patent pending intellectual property for a therapeutic device (the “EZ-G device”) that uses low concentrations of CBD oils, such as hemp seed oil and other natural oils, to treat certain women’s health issues. Under the terms of the share purchase...

Month: September 2022

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals